We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 13, 2018

Venetoclax Plus Tamoxifen in ER− and BCL-2+ Metastatic Breast Cancer

Cancer Discovery

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Discovery
A Phase 1b Dose-Escalation and Expansion Study of the BCL-2 Inhibitor Venetoclax Combined With Tamoxifen in ER and BCL-2-Positive Metastatic Breast Cancer
Cancer Discov 2018 Dec 05;[EPub Ahead of Print], GJ Lindeman, SW Lok, JR Whittle, F Vaillant, CE Teh, LL Lo, AN Policheni, ART Bergin, J Desai, S Ftouni, LC Gandolfo, D Liew, HK Liu, GB Mann, K Moodie, A Murugasu, B Pal, AW Roberts, MA Rosenthal, K Shackleton, MJ Silva, ZR Siow, GK Smyth, L Taylor, A Travers, B Yeo, MM Yeung, A Zivanovic Bujak, SJ Dawson, DHD Gray, JE Visvader

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading